▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #164 by analyst upside · 2026-11-13
TNXP
Tonix Pharmaceuticals Holding Corp.
Healthcare · Market Cap $63M · P/E 0x
ANALYST PRICE TARGET
+949.4%
implied upside to consensus target
Current Price $3.24
Consensus Target $34.0
Bull Target $64.0
Bear Target $18.0
Analysts Covering 5
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
5
Hold
0
Sell
0
52-Week Low $3.21
52-Week High $20.56
YTD Return -80.4%
FUNDAMENTALS
Market Cap $63M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-12.39
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $43M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $3.21
52-Week High $20.56
Current Price $3.24
Bear Target $18.0
Bull Target $64.0
● Now $3.24 ● Target $34.0
TRADING DATA
Avg Volume 734K
YTD Return -80.4%
Analyst Count 5
Consensus Buy
Upside to Target +949.4%
Last Updated 2026-11-13

ANALYST SUMMARY

Tonix Pharmaceuticals Holding Corp. (TNXP) is currently trading at $3.24 with a Wall Street consensus price target of $34.0, implying potential upside of 949.4% over the next 12 months. 5 analysts currently cover TNXP, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $64.0, while the most cautious has a target of $18.0.

TNXP operates in the Healthcare sector with a market capitalisation of $63M. The stock is down 80.4% year-to-date and is currently trading near the lower end of its 52-week range of $3.21 – $20.56.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for TNXP, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Canaccord Genuity ● Initiated
Buy 2026-10-26 Building track record
Raymond James ● Initiated
Strong Buy 2026-06-25 Building track record
TD Cowen ● Initiated
Buy 2026-05-04 Building track record
Noble Capital Markets reit
Outperform → Outperform 2025-03-20 Building track record
Alliance Global Partners - Reiterated
Buy → Buy 2024-07-22 14% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
41
out of 100
Coverage depth
14/30
Consensus clarity
0/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →